Brokerages predict that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will announce earnings per share of ($0.47) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Syros Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.38) and the lowest estimate coming in at ($0.59). Syros Pharmaceuticals posted earnings per share of ($0.54) during the same quarter last year, which suggests a positive year over year growth rate of 13%. The business is scheduled to report its next earnings results on Thursday, March 5th.

According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year earnings of ($1.88) per share for the current fiscal year, with EPS estimates ranging from ($2.01) to ($1.77). For the next year, analysts forecast that the business will report earnings of ($1.93) per share, with EPS estimates ranging from ($2.38) to ($1.56). Zacks’ EPS averages are a mean average based on a survey of research analysts that follow Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01. The business had revenue of $0.56 million for the quarter, compared to analysts’ expectations of $0.43 million. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 84.49%.

A number of equities research analysts have recently commented on the stock. Wedbush cut shares of Syros Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $9.00 price objective on the stock. in a research note on Friday, January 17th. Piper Jaffray Companies dropped their price objective on shares of Syros Pharmaceuticals from $24.00 to $18.00 in a research note on Thursday, October 17th. JMP Securities dropped their price objective on shares of Syros Pharmaceuticals from $18.00 to $16.00 and set a “market outperform” rating on the stock in a research note on Friday, October 18th. ValuEngine raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, February 4th. Finally, Cowen reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $12.89.

A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can grew its stake in Syros Pharmaceuticals by 44.6% in the 4th quarter. Bank of Montreal Can now owns 4,400 shares of the company’s stock valued at $30,000 after acquiring an additional 1,357 shares during the period. Bank of America Corp DE grew its stake in Syros Pharmaceuticals by 10.0% in the 4th quarter. Bank of America Corp DE now owns 15,081 shares of the company’s stock valued at $104,000 after acquiring an additional 1,366 shares during the period. Tower Research Capital LLC TRC grew its stake in Syros Pharmaceuticals by 863.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,688 shares of the company’s stock valued at $28,000 after acquiring an additional 2,409 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Syros Pharmaceuticals by 3.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 205,350 shares of the company’s stock valued at $1,419,000 after acquiring an additional 6,256 shares during the period. Finally, Citigroup Inc. grew its stake in Syros Pharmaceuticals by 175.0% in the 4th quarter. Citigroup Inc. now owns 10,236 shares of the company’s stock valued at $71,000 after acquiring an additional 6,514 shares during the period.

Shares of NASDAQ SYRS traded up $0.33 during midday trading on Friday, reaching $7.87. 111,000 shares of the stock were exchanged, compared to its average volume of 249,803. The firm has a market cap of $320.43 million, a price-to-earnings ratio of -3.99 and a beta of 1.58. Syros Pharmaceuticals has a twelve month low of $4.45 and a twelve month high of $11.93. The firm has a 50-day simple moving average of $7.53 and a two-hundred day simple moving average of $7.68. The company has a quick ratio of 4.92, a current ratio of 4.92 and a debt-to-equity ratio of 0.20.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Read More: How to build a Fibonacci channel

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.